Efficacy of single-dose cholecalciferol in the blood pressure of patients with type 2 diabetes, hypertension and hypovitaminoses D

Tatiana P de Paula, Juliano S R Moreira, Luiza F Sperb, Maria Elisa P Muller, Thais Steemburgo, Luciana V Viana, Tatiana P de Paula, Juliano S R Moreira, Luiza F Sperb, Maria Elisa P Muller, Thais Steemburgo, Luciana V Viana

Abstract

Observational and experimental data reinforce the concept that vitamin D is associated with the pathogenesis of arterial hypertension. We investigated the effect of a single dose of 100,000 IU of cholecalciferol, in office blood pressure (BP), and 24-h ambulatory blood pressure monitoring (ABPM) in patients with type 2 diabetes mellitus (DM), hypertension, and hypovitaminosis D. Forty-three patients were randomized to a placebo or cholecalciferol group. BP was assessed by office measurements and 24-h ABPM, before and after intervention. At week 8, a greater decrease in median ABPM values was observed in cholecalciferol supplementation than in the placebo group for systolic 24-h (- 7.5 vs. - 1; P = 0.02), systolic daytime (- 7 vs. - 1; P = 0.007), systolic nighttime (- 7.0 vs. 3; P = 0.009), diastolic 24-h (- 3.5 vs. - 1; P = 0.037), and daytime DBP (- 5 vs. 0; P = 0.01). Office DBP was also reduced after vitamin D supplementation. A single dose of vitamin D3 improves BP in patients with type 2 diabetes, hypertension, and vitamin D insufficiency, regardless of vitamin D normalization. Vitamin D supplementation could be a valuable tool to treat patients with type 2 DM, hypertension, and hypovitaminosis D.Trial registration: Clinicaltrials.gov NCT02204527.

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Flow diagram showing the included patients.
Figure 2
Figure 2
Systolic and diastolic blood pressure (BP) differences for (A) office BP, (B) ABPM 24 h BP (C) ABPM daytime BP and (D) ABPM nighttime BP. The BP delta (end-of-study minus baseline) is shown as box plots (median is the line within the box, whiskers are 10th and 90th percentiles, the points above and below indicate outliers). Black identifies placebo and red identifies vitamin D group.

References

    1. McGreevy C, Williams D. New insights about vitamin D and cardiovascular disease. Ann. Intern. Med. 2011;155:820–882. doi: 10.7326/0003-4819-155-12-201112200-00004.
    1. Grossman H. Ambulatory blood pressure monitoring in the diagnosis and management of hypertension. Diabetes Care. 2013;36(suppl 2):307–331. doi: 10.2337/dcS13-2039.
    1. Ke L, Mason RS, Kariuki M, Mpofu E, Brock KE. Vitamin D status and hypertension: a review. Integr. Blood Press Control. 2015;8:13–35.
    1. Mirhosseini N, Vatanparast H, Kimball SM. The Association between Serum 25(OH)D status and blood pressure in participants of a community-based prog. Nutrients. 2017;9(11):E1244. doi: 10.3390/nu9111244.
    1. Li YC. Vitamin D: roles in renal and cardiovascular protection. Curr. Opin. Nephrol. Hypertens. 2012;21:72–79. doi: 10.1097/MNH.0b013e32834de4ee.
    1. Zhang W, Chen L, Zhang L, et al. Administration of exogenous 1,25(OH)2D3 normalizes overactivation of the central renin-angiotensin system in 1α(OH)ase knockout mice. Neurosci. Lett. 2015;19(588):184–189. doi: 10.1016/j.neulet.2015.01.013.
    1. Witham M, Adnan Nadir M, Struthers AD. Effect of vitamin D on blood pressure: a systematic review and meta-analysis. J. Hypertens. 2009;27:1948–1954. doi: 10.1097/HJH.0b013e32832f075b.
    1. Beveridge LA, Struthers AD, Khan F, et al. Effect of vitamin D supplementation on blood pressure: a systematic review and meta-analysis incorporating individual patient data. JAMA. 2015;175(5):745–754.
    1. Paula TP, Kramer CK, Viana LV, Azevedo MJ. Effects of individual micronutrients on blood pressure in patients with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. Sci. Rep. 2017;7:40. doi: 10.1038/srep40751.
    1. Vimaleswaran KS, Cavadino A, Berry DJ, et al. Association of vitamin D status with arterial blood pressure and hypertension risk: a mendelian randomisation study. Lancet Diabetes Endocrinol. 2014;2(9):719–729. doi: 10.1016/S2213-8587(14)70113-5.
    1. Shu L, Huang K. Effect of vitamin D supplementation on blood pressure parameters in patients with vitamin deficiency: a systematic review and meta-analysis. J. Am. Soc. Hypertens. 2018;12(7):488–496. doi: 10.1016/j.jash.2018.04.009.
    1. Schulz KF, Altman DG, Moher D, CONSORT Group CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann. Intern. Med. 2010;152(11):726–732. doi: 10.7326/0003-4819-152-11-201006010-00232.
    1. World Medical Association Ethical principles for medical research involving human subjects, 64th WMA General Assembly, Fortaleza, Brazil. JAMA. 2013;310(20):2191–2194. doi: 10.1001/jama.2013.281053.
    1. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206–1252. doi: 10.1161/01.HYP.0000107251.49515.c2.
    1. O’Brien E, Waeber B, Parati G, et al. Blood pressure measuring devices: recommendations of the European Society of Hypertension. BMJ. 2001;322:531–536. doi: 10.1136/bmj.322.7285.531.
    1. Staessen JA, Bieniaszewski L, O’Brien E, et al. Nocturnal blood pressure fall on ambulatory monitoring in a large international database. The “Ad Hoc” Working Group. Hypertension. 1997;29:30–39. doi: 10.1161/01.HYP.29.1.30.
    1. Fagard RH. Dipping pattern of nocturnal blood pressure in patients with hypertension. Expert Rev. Cardiovasc. Ther. 2009;7(6):599–605. doi: 10.1586/erc.09.35.
    1. Moreira JSR, Paula TP, Sperb LF, Miller MEP, Azevedo MJ, Viana LV. Association of plasma vitamin D status with lifestyle patterns and ambulatory blood pressure monitoring parameters in patients with type 2 diabetes and hypertension. Diabetes Res Clin. Pract. 2018;139:139–146. doi: 10.1016/j.diabres.2018.02.038.
    1. Sugden JA, Davies JI, Witham MD, Morris AD, Struthers AD. Vitamin D improves endothelial function in patients with type 2 diabetes mellitus and low vitamin D levels. Diabet. Med. 2008;25:320–325. doi: 10.1111/j.1464-5491.2007.02360.x.
    1. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289(19):2534–2544. doi: 10.1001/jama.289.19.2534.
    1. Fan HQ, Li Y, Thijs L, et al. International database on ambulatory blood pressure in relation to cardiovascular outcomes investigators: prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations. J. Hypertens. 2010;28(10):2036–2045. doi: 10.1097/HJH.0b013e32833b49fe.
    1. Piper MA, Evans CV, Burda BU, Margolis KL, O’Connor E, Whitlock EP. Diagnostic and predictive accuracy of blood pressure screening methods with consideration of rescreening intervals: a systematic review for the U.S. Preventive Services Task Force. Ann. Intern. Med. 2015;162(3):192–204. doi: 10.7326/M14-1539.
    1. Clement DL, De Buyzere ML, De Bacquer DA, et al. Prognostic value of ambulatory blood pressure recordings in patients with treated hypertension. N. Engl. J. Med. 2003;348(24):2407–2415. doi: 10.1056/NEJMoa022273.
    1. Banegas JR, Ruilope RM, de la Sierra A, et al. Relationship between clinic and ambulatory blood-pressure measurements and mortality. N. Engl. J. Med. 2018;378:1509–1520. doi: 10.1056/NEJMoa1712231.
    1. Lurbe E, Redon J, Kesani A, et al. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N. Engl. J. Med. 2002;347(11):797–805. doi: 10.1056/NEJMoa013410.
    1. Leitao CB, Canani LH, Kramer CK, et al. Blood pressure means rather than nocturnal dipping pattern are related to complications in type 2 diabetic patients. Diabet. Med. 2008;25:308–313. doi: 10.1111/j.1464-5491.2007.02354.x.
    1. Mehta R, Drawz PE. Is nocturnal blood pressure reduction the secret to reducing the rate of progression of hypertensive chronic kidney disease? Curr. Hypertens. Rep. 2011;13(5):378–385. doi: 10.1007/s11906-011-0217-8.
    1. Mehrotra R, Kermah DA, Salusky IB, et al. Chronic kidney disease, hypovitaminosis D, and mortality in the United States. Kidney Int. 2009;76:977–983. doi: 10.1038/ki.2009.288.
    1. Witham MD, Dove FJ, Dryburgh M, et al. The effect of different doses of vitamin D3 on markers of vascular health in patients with type 2 diabetes: a randomized controlled trial. Diabetologia. 2010;53:2112–2119. doi: 10.1007/s00125-010-1838-1.
    1. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Hypertension. 2018;71(6):e13–e115.
    1. Nasri H, Behradmanesh S, Ahmadi A, Rafieian-Kopaeiet M. Impact of oral vitamin D (cholecalciferol) replacement therapy on blood pressure in type 2 diabetes patients: a randomized, double-blind, placebo controlled clinical trial. J. Nephropathol. 2014;3:29–33.
    1. Shab-Bidar S, Neyestani TR, Djazayery A, et al. Regular consumption of vitamin D-fortified yogurt drink (Doogh) improved endothelial biomarkers in subjects with type 2 diabetes: a randomized double-blind clinical trial. BMC Med. 2009;9:125–135. doi: 10.1186/1741-7015-9-125.
    1. Loh HH, Lim LL, Yee A, Loh HS. Vethakkan SR Effect of vitamin D replacement in primary hyperparathyroidism with concurrent vitamin D deficiency: a systematic review and meta-analysis. Minerva Endocrinol. 2019;44(2):221. doi: 10.23736/S0391-1977.17.02584-6.
    1. Al-Ali H, Fuleihan GE. Nutritional osteomalacia: substantial clinical improvement and gain in bone density posttherapy. J. Clin. Densitom. 2000;3(1):97. doi: 10.1385/JCD:3:1:097.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj